XML 45 R30.htm IDEA: XBRL DOCUMENT
v3.19.1

Segments of Business and Geographic Areas (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2019
Segment Reporting [Abstract] |
Sales By Segment Of Business | SALES BY SEGMENT OF BUSINESS
|  |  | Fiscal First Quarters Ended
(Dollars in Millions) |  |  | March 31, 2019 |  | April 1, 2018 |  | Percent Change
CONSUMER |  |  |  |  |  |  |
Baby Care |  |  |  |  |  |  |
U.S. |  |  | $ | 87 |  |  | 97 |  |  | (10.9 | )%
International |  |  | 307 |  |  | 360 |  |  | (14.8 | )
Worldwide |  |  | 394 |  |  | 457 |  |  | (14.0 | )
Beauty |  |  |  |  |  |  |
U.S. |  |  | 588 |  |  | 611 |  |  | (3.8 | )
International |  |  | 502 |  |  | 473 |  |  | 6.2 |
Worldwide |  |  | 1,090 |  |  | 1,084 |  |  | 0.6 |
Oral Care |  |  |  |  |  |  |
U.S. |  |  | 151 |  |  | 157 |  |  | (3.5 | )
International |  |  | 216 |  |  | 222 |  |  | (2.8 | )
Worldwide |  |  | 367 |  |  | 379 |  |  | (3.1 | )
OTC |  |  |  |  |  |  |
U.S. |  |  | 507 |  |  | 465 |  |  | 9.1 |
International |  |  | 580 |  |  | 607 |  |  | (4.6 | )
Worldwide |  |  | 1,087 |  |  | 1,072 |  |  | 1.3 |
Women's Health |  |  |  |  |  |  |
U.S. |  |  | 3 |  |  | 3 |  |  | 4.2 |
International |  |  | 222 |  |  | 240 |  |  | (7.5 | )
Worldwide |  |  | 225 |  |  | 243 |  |  | (7.3 | )
Wound Care/Other |  |  |  |  |  |  |
U.S. |  |  | 102 |  |  | 103 |  |  | (0.9 | )
International |  |  | 53 |  |  | 60 |  |  | (11.6 | )
Worldwide |  |  | 155 |  |  | 163 |  |  | (4.8 | )
TOTAL CONSUMER |  |  |  |  |  |  |
U.S. |  |  | 1,438 |  |  | 1,436 |  |  | 0.2 |
International |  |  | 1,880 |  |  | 1,962 |  |  | (4.2 | )
Worldwide |  |  | 3,318 |  |  | 3,398 |  |  | (2.4 | )
PHARMACEUTICAL |  |  |  |  |  |  |
Immunology |  |  |  |  |  |  |
U.S. |  |  | 2,163 |  |  | 2,000 |  |  | 8.1 |
International |  |  | 1,088 |  |  | 1,042 |  |  | 4.5 |
Worldwide |  |  | 3,251 |  |  | 3,042 |  |  | 6.9 |
REMICADE® |  |  |  |  |  |  |
U.S. |  |  | 774 |  |  | 916 |  |  | (15.5 | )
U.S. Exports |  |  | 76 |  |  | 142 |  |  | (46.4 | )
International |  |  | 252 |  |  | 331 |  |  | (23.6 | )
Worldwide |  |  | 1,102 |  |  | 1,389 |  |  | (20.6 | )
SIMPONI / SIMPONI ARIA® |  |  |  |  |  |  |
U.S. |  |  | 263 |  |  | 224 |  |  | 17.0 |
International |  |  | 261 |  |  | 294 |  |  | (11.1 | )
Worldwide |  |  | 524 |  |  | 518 |  |  | 1.0 |
STELARA® |  |  |  |  |  |  |
U.S. |  |  | 882 |  |  | 652 |  |  | 35.2 |
International |  |  | 523 |  |  | 409 |  |  | 27.9 |
Worldwide |  |  | 1,405 |  |  | 1,061 |  |  | 32.4 |
TREMFYA® |  |  |  |  |  |  |
U.S. |  |  | 168 |  |  | 66 |  |  | *
International |  |  | 49 |  |  | 6 |  |  | *
Worldwide |  |  | 217 |  |  | 72 |  |  | *
OTHER IMMUNOLOGY |  |  |  |  |  |  |
U.S. |  |  | — |  |  | — |  |  | —
International |  |  | 3 |  |  | 2 |  |  | 19.5
Worldwide |  |  | 3 |  |  | 2 |  |  | 19.5
Infectious Diseases |  |  |  |  |  |  |
U.S. |  |  | 357 |  |  | 333 |  |  | 7.3 |
International |  |  | 489 |  |  | 497 |  |  | (1.7 | )
Worldwide |  |  | 846 |  |  | 830 |  |  | 1.9 |
EDURANT® / rilpivirine |  |  |  |  |  |  |
U.S. |  |  | 12 |  |  | 14 |  |  | (18.8 | )
International |  |  | 199 |  |  | 196 |  |  | 2.2 |
Worldwide |  |  | 211 |  |  | 210 |  |  | 0.8 |
PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® |  |  |  |  |  |  |
U.S. |  |  | 315 |  |  | 273 |  |  | 15.5 |
International |  |  | 208 |  |  | 205 |  |  | 1.5 |
Worldwide |  |  | 523 |  |  | 478 |  |  | 9.5 |
OTHER INFECTIOUS DISEASES |  |  |  |  |  |  |
U.S. |  |  | 30 |  |  | 46 |  |  | (33.8 | )
International |  |  | 82 |  |  | 96 |  |  | (16.0 | )
Worldwide |  |  | 112 |  |  | 142 |  |  | (21.7 | )
Neuroscience |  |  |  |  |  |  |
U.S. |  |  | 723 |  |  | 624 |  |  | 16.0 |
International |  |  | 905 |  |  | 935 |  |  | (3.2 | )
Worldwide |  |  | 1,629 |  |  | 1,559 |  |  | 4.5 |
CONCERTA® / Methylphenidate |  |  |  |  |  |  |
U.S. |  |  | 97 |  |  | 66 |  |  | 47.7 |
International |  |  | 116 |  |  | 107 |  |  | 8.5 |
Worldwide |  |  | 214 |  |  | 173 |  |  | 23.4 |
INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® |  |  |  |  |  |  |
U.S. |  |  | 483 |  |  | 400 |  |  | 20.7 |
International |  |  | 307 |  |  | 296 |  |  | 3.8 |
Worldwide |  |  | 790 |  |  | 696 |  |  | 13.5 |
RISPERDAL CONSTA® |  |  |  |  |  |  |
U.S. |  |  | 77 |  |  | 82 |  |  | (6.8 | )
International |  |  | 102 |  |  | 114 |  |  | (10.3 | )
Worldwide |  |  | 179 |  |  | 196 |  |  | (8.8 | )
OTHER NEUROSCIENCE |  |  |  |  |  |  |
U.S. |  |  | 66 |  |  | 76 |  |  | (12.0 | )
International |  |  | 379 |  |  | 418 |  |  | (9.2 | )
Worldwide |  |  | 446 |  |  | 494 |  |  | (9.6 | )
Oncology |  |  |  |  |  |  |
U.S. |  |  | 962 |  |  | 933 |  |  | 3.1 |
International |  |  | 1,556 |  |  | 1,378 |  |  | 13.0 |
Worldwide |  |  | 2,518 |  |  | 2,311 |  |  | 9.0 |
DARZALEX® |  |  |  |  |  |  |
U.S. |  |  | 352 |  |  | 264 |  |  | 33.0 |
International |  |  | 277 |  |  | 168 |  |  | 65.1 |
Worldwide |  |  | 629 |  |  | 432 |  |  | 45.5 |
IMBRUVICA® |  |  |  |  |  |  |
U.S. |  |  | 349 |  |  | 227 |  |  | 53.7 |
International |  |  | 435 |  |  | 360 |  |  | 20.8 |
Worldwide |  |  | 784 |  |  | 587 |  |  | 33.5 |
VELCADE® |  |  |  |  |  |  |
U.S. |  |  | — |  |  | — |  |  | — |
International |  |  | 263 |  |  | 313 |  |  | (16.0 | )
Worldwide |  |  | 263 |  |  | 313 |  |  | (16.0 | )
ZYTIGA® / abiraterone acetate |  |  |  |  |  |  |
U.S. |  |  | 185 |  |  | 407 |  |  | (54.5 | )
International |  |  | 494 |  |  | 438 |  |  | 12.9 |
Worldwide |  |  | 679 |  |  | 845 |  |  | (19.6 | )
OTHER ONCOLOGY |  |  |  |  |  |  |
U.S. |  |  | 76 |  |  | 35 |  |  | * |
International |  |  | 87 |  |  | 99 |  |  | (12.2 | )
Worldwide |  |  | 163 |  |  | 134 |  |  | 21.7 |
Pulmonary Hypertension |  |  |  |  |  |  |
U.S. |  |  | 430 |  |  | 361 |  |  | 19.2 |
International |  |  | 226 |  |  | 224 |  |  | 0.7 |
Worldwide |  |  | 656 |  |  | 585 |  |  | 12.1 |
OPSUMIT® |  |  |  |  |  |  |
U.S. |  |  | 172 |  |  | 149 |  |  | 15.9 |
International |  |  | 133 |  |  | 122 |  |  | 8.9 |
Worldwide |  |  | 306 |  |  | 271 |  |  | 12.7 |
TRACLEER® |  |  |  |  |  |  |
U.S. |  |  | 61 |  |  | 68 |  |  | (10.1 | )
International |  |  | 56 |  |  | 72 |  |  | (22.9 | )
Worldwide |  |  | 117 |  |  | 140 |  |  | (16.7 | )
UPTRAVI® |  |  |  |  |  |  |
U.S. |  |  | 176 |  |  | 124 |  |  | 41.4 |
International |  |  | 22 |  |  | 16 |  |  | 42.8 |
Worldwide |  |  | 198 |  |  | 140 |  |  | 41.6 |
OTHER |  |  |  |  |  |  |
U.S. |  |  | 21 |  |  | 20 |  |  | 3.6 |
International |  |  | 15 |  |  | 14 |  |  | 4.6 |
Worldwide |  |  | 35 |  |  | 34 |  |  | 4.0 |
Cardiovascular / Metabolism / Other |  |  |  |  |  |  |
U.S. |  |  | 947 |  |  | 1,103 |  |  | (14.1 | )
International |  |  | 398 |  |  | 414 |  |  | (3.9 | )
Worldwide |  |  | 1,345 |  |  | 1,517 |  |  | (11.3 | )
XARELTO® |  |  |  |  |  |  |
U.S. |  |  | 542 |  |  | 578 |  |  | (6.3 | )
International |  |  | — |  |  | — |  |  | — |
Worldwide |  |  | 542 |  |  | 578 |  |  | (6.3 | )
INVOKANA® / INVOKAMET® |  |  |  |  |  |  |
U.S. |  |  | 154 |  |  | 204 |  |  | (24.8 | )
International |  |  | 49 |  |  | 44 |  |  | 11.6 |
Worldwide |  |  | 202 |  |  | 248 |  |  | (18.4 | )
PROCRIT® / EPREX® |  |  |  |  |  |  |
U.S. |  |  | 148 |  |  | 189 |  |  | (21.6 | )
International |  |  | 78 |  |  | 87 |  |  | (10.2 | )
Worldwide |  |  | 226 |  |  | 276 |  |  | (18.0 | )
OTHER |  |  |  |  |  |  |
U.S. |  |  | 104 |  |  | 132 |  |  | (21.3 | )
International |  |  | 271 |  |  | 283 |  |  | (4.4 | )
Worldwide |  |  | 374 |  |  | 415 |  |  | (9.7 | )
TOTAL PHARMACEUTICAL |  |  |  |  |  |  |
U.S. |  |  | 5,582 |  |  | 5,354 |  |  | 4.3 |
International |  |  | 4,662 |  |  | 4,490 |  |  | 3.9 |
Worldwide |  |  | 10,244 |  |  | 9,844 |  |  | 4.1 |
MEDICAL DEVICES |  |  |  |  |  |  |
Diabetes Care |  |  |  |  |  |  |
U.S. |  |  | — |  |  | 117 |  |  | * |
International |  |  | — |  |  | 222 |  |  | * |
Worldwide |  |  | — |  |  | 339 |  |  | * |
Interventional Solutions |  |  |  |  |  |  |
U.S. |  |  | 343 |  |  | 304 |  |  | 12.6 |
International |  |  | 389 |  |  | 336 |  |  | 15.8 |
Worldwide |  |  | 732 |  |  | 640 |  |  | 14.3 |
Orthopaedics |  |  |  |  |  |  |
U.S. |  |  | 1,318 |  |  | 1,307 |  |  | 0.9 |
International |  |  | 885 |  |  | 943 |  |  | (6.2 | )
Worldwide |  |  | 2,204 |  |  | 2,250 |  |  | (2.1 | )
HIPS |  |  |  |  |  |  |
U.S. |  |  | 213 |  |  | 209 |  |  | 2.1 |
International |  |  | 148 |  |  | 154 |  |  | (3.8 | )
Worldwide |  |  | 361 |  |  | 363 |  |  | (0.4 | )
KNEES |  |  |  |  |  |  |
U.S. |  |  | 223 |  |  | 228 |  |  | (2.2 | )
International |  |  | 146 |  |  | 159 |  |  | (8.2 | )
Worldwide |  |  | 369 |  |  | 387 |  |  | (4.7 | )
TRAUMA |  |  |  |  |  |  |
U.S. |  |  | 417 |  |  | 407 |  |  | 2.5 |
International |  |  | 268 |  |  | 289 |  |  | (7.0 | )
Worldwide |  |  | 685 |  |  | 696 |  |  | (1.4 | )
SPINE & OTHER |  |  |  |  |  |  |
U.S. |  |  | 465 |  |  | 463 |  |  | 0.3 |
International |  |  | 323 |  |  | 341 |  |  | (5.5 | )
Worldwide |  |  | 788 |  |  | 804 |  |  | (2.2 | )
Surgery |  |  |  |  |  |  |
U.S. |  |  | 1,001 |  |  | 993 |  |  | 0.8 |
International |  |  | 1,394 |  |  | 1,430 |  |  | (2.6 | )
Worldwide |  |  | 2,395 |  |  | 2,423 |  |  | (1.2 | )
ADVANCED |  |  |  |  |  |  |
U.S. |  |  | 404 |  |  | 393 |  |  | 2.9 |
International |  |  | 576 |  |  | 573 |  |  | 0.5 |
Worldwide |  |  | 980 |  |  | 966 |  |  | 1.5 |
GENERAL |  |  |  |  |  |  |
U.S. |  |  | 425 |  |  | 423 |  |  | 0.3 |
International |  |  | 665 |  |  | 704 |  |  | (5.6 | )
Worldwide |  |  | 1,089 |  |  | 1,127 |  |  | (3.4 | )
SPECIALTY |  |  |  |  |  |  |
U.S. |  |  | 172 |  |  | 177 |  |  | (2.5 | )
International |  |  | 153 |  |  | 153 |  |  | (0.2 | )
Worldwide |  |  | 325 |  |  | 330 |  |  | (1.4 | )
Vision |  |  |  |  |  |  |
U.S. |  |  | 446 |  |  | 440 |  |  | 1.5 |
International |  |  | 682 |  |  | 675 |  |  | 1.1 |
Worldwide |  |  | 1,129 |  |  | 1,115 |  |  | 1.2 |
CONTACT LENSES / OTHER |  |  |  |  |  |  |
U.S. |  |  | 321 |  |  | 309 |  |  | 4.1 |
International |  |  | 502 |  |  | 498 |  |  | 1.0 |
Worldwide |  |  | 824 |  |  | 807 |  |  | 2.1 |
SURGICAL |  |  |  |  |  |  |
U.S. |  |  | 125 |  |  | 131 |  |  | (4.5 | )
International |  |  | 180 |  |  | 177 |  |  | 1.3 |
Worldwide |  |  | 305 |  |  | 308 |  |  | (1.1 | )
TOTAL MEDICAL DEVICES |  |  |  |  |  |  |
U.S. |  |  | 3,109 |  |  | 3,161 |  |  | (1.6 | )
International |  |  | 3,350 |  |  | 3,606 |  |  | (7.1 | )
Worldwide |  |  | 6,459 |  |  | 6,767 |  |  | (4.6 | )
WORLDWIDE |  |  |  |  |  |  |
U.S. |  |  | 10,129 |  |  | 9,951 |  |  | 1.8 |
International |  |  | 9,892 |  |  | 10,058 |  |  | (1.7 | )
Worldwide |  |  | $ | 20,021 |  |  | 20,009 |  |  | 0.1 | %
*Percentage greater than 100% or not meaningful
Operating Profit by Segment of Business | EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT
|  |  | Fiscal First Quarters Ended
(Dollars in Millions) |  |  | March 31, 2019 |  | April 1, 2018 |  | Percent Change
Consumer (1) |  |  | $ | 741 |  |  | 548 |  |  | 35.2 | %
Pharmaceutical(2) |  |  | 2,331 |  |  | 3,666 |  |  | (36.4 | )
Medical Devices(3) |  |  | 1,497 |  |  | 1,579 |  |  | (5.2 | )
Segment earnings before provision for taxes |  |  | 4,569 |  |  | 5,793 |  |  | (21.1 | )
Less: Expense not allocated to segments (4) |  |  | 147 |  |  | 312 |  |  |  |
Worldwide income before tax |  |  | $ | 4,422 |  |  | 5,481 |  |  | (19.3 | )%
(1) Includes a gain of $0.3 billion related to the Company's previously held equity investment in Ci:z Holdings Co., Ltd. (Dr. Ci: Labo) Includes amortization expense of $0.1 billion and $0.1 billion in the fiscal first quarters of 2019 and 2018, respectively. (2) Includes an in-process research and development expense of $0.9 billion related to the Alios asset, litigation expense of $0.3 billion and an unrealized gain on securities of $0.1 billion in the fiscal first quarter of 2019. Additionally, the fiscal first quarter of 2019 includes increased research and development expense primarily $0.3 billion related to an upfront payment to argenx and increased investment to advance the pipeline. Includes Actelion acquisition related costs of $0.1 billion in the fiscal first quarter of 2018. Includes amortization expense of $0.8 billion and $0.8 billion in the fiscal first quarters of 2019 and 2018, respectively. (3) Includes a restructuring related charge of $0.1 billion and $0.1 billion in the fiscal first quarters of 2019 and 2018, respectively. Includes litigation expense of $0.1 billion in the fiscal first quarter of 2019. Includes amortization expense of $0.2 billion and $0.3 billion in the fiscal first quarters of 2019 and 2018, respectively. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas | SALES BY GEOGRAPHIC AREA
|  |  | Fiscal First Quarters Ended
(Dollars in Millions) |  |  | March 31, 2019 |  | April 1, 2018 |  | Percent Change
United States |  |  | $ | 10,129 |  |  | 9,951 |  |  | 1.8 | %
Europe |  |  | 4,609 |  |  | 4,797 |  |  | (3.9 | )
Western Hemisphere, excluding U.S. |  |  | 1,503 |  |  | 1,567 |  |  | (4.1 | )
Asia-Pacific, Africa |  |  | 3,780 |  |  | 3,694 |  |  | 2.3 |
Total |  |  | $ | 20,021 |  |  | 20,009 |  |  | 0.1 | %

X
- Definition Sales by segment of business. + References No definition available. + Details
Name: | jnj_SalesBySegmentOfBusinessTableTextBlock
Namespace Prefix: | jnj_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration